Oncotelic Therapeutics, Inc.
OTLC
Rank in Stocks
#29394
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage... Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 β an antisense compound designed to inhibit TGF-Γ2 β is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Share Price
$0.0173
Last synced: 2026-11-09
Market Cap
$7.91M
Change (1 day)
73.00%
Change (1 year)
-80.25%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncotelic Therapeutics, Inc. (OTLC)
Category
Healthcare
Operating Margin for Oncotelic Therapeutics, Inc. (OTLC)
Operating Margin as of November 2026 TTM: -2,286.59%
According to Oncotelic Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is -2,286.59%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Oncotelic Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,286.59% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -9,497.16% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | -435.69% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | 3,002,000.00% | -78.31% |
| 2017 | 13,842,000.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -13,315.79% | 52.78% |
| 2013 | -8,715.79% | 68.44% |
| 2012 | -5,174.36% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | -100.00% |
| 2008 | -216,166.67% | 16.46% |
| 2007 | -185,608.33% | 0.00% |
| 2006 | 0.00% | -100.00% |
| 2005 | -1,304,800.00% | 771.53% |
| 2004 | -149,714.29% | 383.57% |
| 2003 | -30,960.00% | 741.70% |
| 2002 | -3,678.28% | 10,188.90% |
| 2001 | -35.75% | -94.44% |
| 2000 | -643.52% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.93% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oncotelic Therapeutics, Inc.'s operating margin
What is Oncotelic Therapeutics, Inc.'s operating margin?
Oncotelic Therapeutics, Inc.'s operating margin is -2,286.59%, as of Nov 2026.
What was Oncotelic Therapeutics, Inc.'s operating margin in 2025?
In 2025, Oncotelic Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Oncotelic Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Oncotelic Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2023 (-9,497.16%).
How does Oncotelic Therapeutics, Inc.'s operating margin compare with similar companies?
Oncotelic Therapeutics, Inc.'s operating margin (-2,286.59%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.